Merus’s big bispecific test approaches
Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?
Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?
Abstract titles reveal some of ASCO’s key datasets.
Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.
After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.
One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.
The company's comparison of its ADCs to Enhertu seems farfetched.
Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.